No quarterly revenue total was found in BIOFORCE NANOSCIENCES HOLDINGS, INC.'s SEC filings.
Bioforce Nanosciences Holdings, Inc. (BFNH) files with the SEC under industry code 3826, Laboratory Analytical Instruments.
Revenue
—
Net income
$238,682
+294.4% vs year-ago quarter
Operating cash flow
$-26,980
+3.3% vs year-ago quarter
Free cash flow
—
EPS
$0.01
Dividend per share
None
Shares outstanding
33.55M
+0.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BFNH (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Virginia Beach, VA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1310488
- Former names
- SILVER RIVER VENTURES, INC. (until Feb 24, 2006)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | — | — | — | -$115,915 | -$122,781 |
| Net income | $238,682 | -$102,411 | -$118,605 | -$115,915 | -$122,781 |
| Diluted EPS | $0.01 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$26,980 | $7,088 | -$10,921 | -$11,121 | -$27,893 |
| Total assets | $2.4M | $6,347 | $786 | $784 | $905 |
| Total liabilities | $84,767 | $727,301 | $619,329 | $500,722 | $384,928 |
| Stockholders' equity | $2.3M | -$720,954 | -$618,543 | -$499,938 | -$384,023 |
| Cash and investments | $307 | $6,347 | $786 | $784 | $905 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 4, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 18, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 7, 2026 | Jul 1, 2026 |
All 253 Bioforce Nanosciences Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.